Oct. 24 at 4:49 PM
$PDSB I was watching Adverum for quite a while, they went low on cash, but had a promising phase 3 trial running. Today they were bought by Eli Lilly. I guess the same will happen to
$PDSB.
I asked Microsoft Copilot to assess the value of
$PDSB 's pipeline, and this was the result:
Estimated Pipeline Value (Indicative Only)
While no formal valuation has been published, biotech analysts often use risk-adjusted net present value (rNPV) models. Based on comparable immunotherapy platforms and Fast Track assets, rough estimates suggest:
PDS0101 alone could be worth
$150M–
$300M if Phase 3 confirms survival benefit and leads to FDA approval
The entire pipeline might be valued at
$250M–
$500M in a favorable scenario, assuming partnerships or licensing deals.
